- Wisconsin-Based Resident Psychiatrist Calls on the FDA to Immediately Allow the Administration of Psychedelics Like Psilocybin (Magic Mushrooms), MDMA and LSD to Help Patients That are Suffering as a Result of the Coronavirus Pandemic
Wisconsin-based resident psychiatrist Dr. Morgan Campbell is calling on the U.S. Food and Drug Administration (FDA) to temporarily approve psychedelic therapies to help aid struggling patients of the COVID-19 pandemic.
This week, Dr. Campbell wrote an article in the Sacramento Bee publication urging the FDA to circumvent its typical approval protocols to allow psychiatrists and therapists to immediately begin administering psychedelic substances like Psilocybin (Magic Mushrooms), MDMA and LSD to certain Coronavirus-related patients.
Dr. Campbell believes these psychedelic drugs, which have shown tremendous medical promise, could help patients currently suffering from conditions such as PTSD, depression and anxiety as a result of COVID-19.
In his opinion piece, Dr. Campbell lays out his case for the rapid approval of psychedelic therapies to address what he says will be an “inevitable spike of mental illnesses.”
Recently, the FDA, along with Health Canada, has granted Psilocybin and MDMA “Breakthrough Status,” meaning that the FDA is already expediting development and review of these two psychedelics because they “may demonstrate substantial improvement over other therapy on a clinically significant endpoint.”
In response to the recent move by the FDA to relax its regulations relating to Coronavirus therapies, Dr. Campbell wrote the following:
“Last month, the FDA relaxed regulations in the approval process for COVID-19 therapies, because addressing the problem faster can flatten the curve. This means keeping the health infrastructure from being overwhelmed by new cases. Speedily addressing psychiatric issues with the best therapies available can similarly protect our healthcare system.”
While it’s true, these substances carry certain risks as well as the long-standing stigma of being considered party drugs. Still, the growing number of clinical studies are proving that when administered in precision doses under medical supervision, the benefits can far outweigh any risk.
“Because of how many years MDMA and psilocybin have been tested for safety and efficacy, there is better quality evidence for these psychedelics than the evidence that will be required to approve COVID-19 antivirals. An important difference, however, is the stigma surrounding psychedelics,” added Dr. Campbell.
Dr. Campbell references an MDMA study that is currently taking place in the United States, Canada and Israel that is expected to be completed in 2021. He concludes his article by saying: “As we await definitive results from these trials, let us grant temporary approval to psychedelics to protect our healthcare infrastructures and save lives.”
Read Dr. Morgan Campbell’s Introducing ‘Brainsplain’
Video: From Nightmares to Ecstasy: Can MDMA Help with PTSD?
Video Source: Brainsplain YouTube